DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

DXCM earnings call for the period ending December 31, 2024.

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Continuous glucose monitoring (CGM) devices provide real-time blood sugar readings 24 hours a day, allowing people with type 1 or type 2 diabetes to closely track blood glucose levels and trends. Most ...

Managing blood sugar levels is a constant balancing act, particularly for individuals with diabetes. But, life doesn’t stand still. Times of change – be it shifts in routine, increased stress, or even ...